A shadow is falling across the UK’s pharmacies, not from a lack of medication itself, but from a crisis brewing in global trade. The conflict in the Middle East has effectively choked the Strait of Hormuz, a vital artery for oil tankers and cargo ships connecting the Persian Gulf to the world.
This disruption isn’t just about fuel prices; it’s a silent threat to the supply of essential medicines. Manufacturing relies on key ingredients, and shipping costs have doubled as companies scramble to find alternative, often slower, routes. The UK, heavily reliant on imports – producing only about one in four drugs domestically – is particularly vulnerable.
The problem is compounded by the delicate nature of many medications. Cancer treatments and other life-sustaining drugs have limited shelf lives, making lengthy detours a dangerous gamble. Beyond the drugs themselves, the very materials used to package them – plastics derived from oil – are becoming more expensive and harder to secure.
Pharmacies operate under a strict “drug tariff,” a fixed price the NHS will cover. When global price hikes push a drug’s cost above this limit, pharmacies must seek a “price concession” from the government. Recently, the number of drugs requiring concessions has exploded, reaching a record 204 in April alone – a stark indicator of the mounting pressure.
The situation isn’t a straightforward shortage, but a financial strain. James Davies, of Community Pharmacy England, explains that the record concessions signal a supply chain under immense pressure, a pressure only expected to worsen. Even NHS England’s head, Jim Mackey, admits to being “really worried” about the looming challenges.
The reality for pharmacists is grim. They are increasingly forced to choose between dispensing medications at a loss – impacting their own livelihoods – or sending patients on frustrating journeys to other pharmacies, sometimes miles away. One pharmacist detailed losing over £1,000 a month on a single medication, Apixaban, due to the price disparity.
This crisis unfolds against a backdrop of declining pharmacy numbers in the UK, poised to fall below 10,000 for the first time in two decades. Experts also point to the issue of over-prescription, with limited resources hindering efforts to safely “de-prescribe” medications patients may no longer need.
Specific medications are already feeling the pinch. ADHD medication like Methylphenidate (Ritalin) is in short supply, as are treatments for heart conditions like propranolol and ramipril. A “serious shortage” notice has been issued for ramipril capsules, limiting patients to one month’s supply at a time.
The consequences are devastating. Apixaban, crucial for preventing dangerous blood clots, is becoming harder to obtain. Ongoing shortages of aspirin and oxybutynin, used in hormone replacement therapy, add to the growing concern. Tragically, the Epilepsy Society has linked at least three deaths in the past two years to the unavailability of essential anti-seizure medication, like Tegretol.
One man, David Crompton, fell down stairs in December after being unable to access his prescribed medication. For many with epilepsy, there simply is no alternative when their lifeline is cut off. The situation demands urgent attention and a proactive strategy to safeguard the nation’s health.
The Department of Health and Social Care maintains that the majority of medicines remain in good supply and that they are actively working to address price increases through adjustments to reimbursement rates. However, the escalating crisis and the stories emerging from pharmacies paint a far more troubling picture.
